Menu
Search
|

Menu

Close
X

AzurRx BioPharma Inc AZRX.OQ (NASDAQ Stock Exchange Capital Market)

2.83 USD
+0.01 (+0.35%)
As of Feb 23
chart
Previous Close 2.82
Open 2.85
Volume 24,032
3m Avg Volume 9,683
Today’s High 2.89
Today’s Low 2.71
52 Week High 5.25
52 Week Low 2.40
Shares Outstanding (mil) 11.23
Market Capitalization (mil) 40.32
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-0.836
FY16
-1.737
FY15
-0.944
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
8.59
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
14.45
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
--
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Edward Borkowski
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Maged Shenouda
Chief Financial Officer, Executive Vice President - Corporate Development & Independent Director, Since 2017
Salary: --
Bonus: --
Daniel Dupret
Chief Scientific Officer, Since
Salary: $204,675.00
Bonus: --
Charles Casamento
Director, Since 2017
Salary: --
Bonus: --
Vern Schramm
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

760 Parkside Ave Ste 304
BROOKLYN   NY   11226-1784

Phone: +1646.6997855

AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).

SPONSORED STORIES